<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770012</url>
  </required_header>
  <id_info>
    <org_study_id>2020-version 1.0</org_study_id>
    <nct_id>NCT04770012</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy in Heart Transplantation</brief_title>
  <official_title>Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac allograft vasculopathy is a common complication affecting heart transplant patients.&#xD;
      This condition causes narrowing of the heart arteries leading to graft dysfunction. The&#xD;
      research team is investigating whether early antiplatelet therapy post heart transplant can&#xD;
      prevent the development of CAV. This study will determine the feasibility of a large&#xD;
      multicenter randomized placebo-controlled trial to answer this question.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart transplant patients who fulfill selection criteria will undergo baseline clinical&#xD;
      evaluation and data collection. Participants will be randomized to either placebo, aspirin or&#xD;
      clopidogrel to be taken daily for the duration of the study. Patients will undergo invasive&#xD;
      coronary studies (angiography, optical coherence tomography and intracoronary flow) and&#xD;
      platelet function testing at 2 and 12 months post heart transplant. In addition, angiography&#xD;
      will be performed at 24 months post heart transplant and thereafter according to&#xD;
      institutional protocol. The primary analysis will determine the feasibility of conducting a&#xD;
      large multicenter randomized placebo controlled trial by assessing recruitment rates, event&#xD;
      rates, treatment crossovers and loss to follow-up. Secondary analyses will include assessing&#xD;
      the effect of antiplatelet treatment on angiographic CAV, coronary intimal disease on optical&#xD;
      coherence tomography, coronary macrovascular and microvascular function by intracoronary flow&#xD;
      measures, and platelet function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:2:1 randomization to placebo-control, aspirin 81 mg daily or clopidogrel 75 mg daily</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients, clinical care providers and research staff will be blinded to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: Recruitment rate</measure>
    <time_frame>3 years</time_frame>
    <description>Average recruitment rate of 4.5 patients per month at 3 study sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: CAV event rate</measure>
    <time_frame>3 years</time_frame>
    <description>2-year CAV event rate of &gt;8%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Treatment cross over rate</measure>
    <time_frame>3 years</time_frame>
    <description>Crossover from aspirin to placebo &lt;2%, clopidogrel to placebo &lt;2%, placebo to aspirin &lt;4%, placebo to clopidogrel &lt;1%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Loss to follow up rate</measure>
    <time_frame>3 years</time_frame>
    <description>Loss-to-follow-up &lt;1%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Compliance to treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Compliance to treatment &gt;80%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac allograft vasculopathy</measure>
    <time_frame>1 and 2 years post transplant</time_frame>
    <description>Angiographic CAV disease severity according to ISHLT CAV 0-3 grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary intimal disease</measure>
    <time_frame>2 months, 1 year post transplant</time_frame>
    <description>Coronary intimal volume measured on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary endothelial function</measure>
    <time_frame>2 months and 1 year post transplant</time_frame>
    <description>Coronary flow reserve measured by intracoronary flow assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary macrovascular function</measure>
    <time_frame>2 months and 1 year post transplant</time_frame>
    <description>Fractional flow reserve measured by intracoronary flow assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary microvascular function</measure>
    <time_frame>2 months and 1 year post transplant</time_frame>
    <description>Index of microcirculatory resistance measured by intracoronary flow assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Function</measure>
    <time_frame>Baseline, 2 months and 1 year post transplant</time_frame>
    <description>Assessment of response to antiplatelet therapy using Enzyme-Linked Immunosorbent Assays (ELISA) for thromboxane B2 and Vasodilator Stimulated Phosphoprotein (VASP).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Cardiac Allograft Vasculopathy</condition>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment</description>
    <arm_group_label>aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Heart transplant&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or known intolerance to aspirin&#xD;
&#xD;
          2. Allergy or known intolerance to clopidogrel&#xD;
&#xD;
          3. Intracranial hemorrhage ≤14 days&#xD;
&#xD;
          4. Bleeding disorder&#xD;
&#xD;
          5. Platelet count &lt;50 x 109/L&#xD;
&#xD;
          6. History of aspirin related gastrointestinal bleeding or ulcers&#xD;
&#xD;
          7. Non-cardiac indication for antiplatelet therapy&#xD;
&#xD;
          8. Anticoagulation &gt;3 months&#xD;
&#xD;
          9. Allergy to iodinated contrast&#xD;
&#xD;
         10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30&#xD;
             mL/min/1.73 m2 for non-dialysis patients&#xD;
&#xD;
         11. Unable to undergo coronary angiography due to unsuitable vascular access&#xD;
&#xD;
         12. Combined solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chih</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Chih</last_name>
    <phone>613-696-7000</phone>
    <email>schih@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Ross</last_name>
    <email>heather.ross@uhn.ca</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

